Literature DB >> 6171056

A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals.

C A Kimmel, C Trammell.   

Abstract

A simple, rapid procedure for dual staining of cartilage and bone in rodents, particularly in late gestation, has been developed for routine use. The procedure involves rapid, complete skinning of fresh eviscerated specimens following a 30 sec immersion in a 70 C water bath. The unfixed specimen is stained in a mixture of 0.14% Alcian blue and 0.12% alizarin red S in ethanol and glacial acetic acid. Specimens are then macerated in 2% KOH, cleared and hardened in 1:1 glycerin and distilled water, and stored in pure glycerin. Rapid staining of cartilage only is done in a mixture of 0.08% Alcian blue, glacial acetic acid, and ethanol, with subsequent maceration, clearing, and hardening as in the double staining procedure. Rapid staining of bone only, concurrent with maceration of soft tissue, can be done by placing fresh, unskinned specimens in a diluted mixture of alizarin red S in 2% KOH, with subsequent clearing and hardening in 1:1 distilled water and glycerin. Good quality fetal specimens can be prepared for examination by any of these procedures in a minimum of 11/2-2 days as compared to a minimum of 4-5 days for other procedures. Double stained specimens can be examined for abnormalities of the cartilage as well as bone.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171056     DOI: 10.3109/10520298109067325

Source DB:  PubMed          Journal:  Stain Technol        ISSN: 0038-9153


  33 in total

1.  Development of the post-natal growth plate requires intraflagellar transport proteins.

Authors:  Buer Song; Courtney J Haycraft; Hwa-seon Seo; Bradley K Yoder; Rosa Serra
Journal:  Dev Biol       Date:  2007-02-12       Impact factor: 3.582

2.  The effects of paralysis on skeletal development in the chick embryo. I. General effects.

Authors:  A Hosseini; D A Hogg
Journal:  J Anat       Date:  1991-08       Impact factor: 2.610

3.  Tgfbr2 is required in osterix expressing cells for postnatal skeletal development.

Authors:  Sarah B Peters; Ying Wang; Rosa Serra
Journal:  Bone       Date:  2016-12-30       Impact factor: 4.398

4.  Embryotoxicity and teratogenicity of some derivatives of chloroethylaminophenylacetic acid.

Authors:  V Zalgeviciené; J Zukiené; G Grazeliené; G Sinkeviciúté; J Didziapetriené
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

5.  An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.

Authors:  P D Aplan; C A Jones; D S Chervinsky; X Zhao; M Ellsworth; C Wu; E A McGuire; K W Gross
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

6.  Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.

Authors:  Bogdan J Wlodarczyk; Krystal Ogle; Linda Ying Lin; Meir Bialer; Richard H Finnell
Journal:  Bipolar Disord       Date:  2015-08-20       Impact factor: 6.744

7.  Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme results in defects in development of the long bones and joints.

Authors:  Hwa-Seon Seo; Rosa Serra
Journal:  Dev Biol       Date:  2007-08-09       Impact factor: 3.582

8.  Embryotoxicity induced by alkylating agents: left-sided preponderance of paw malformations induced by acetoxymethyl-methylnitrosamine in mice.

Authors:  G Bochert; T Platzek; G Blankenburg; M Wiessler; D Neubert
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

9.  Expression of a partially deleted gene of human type II procollagen (COL2A1) in transgenic mice produces a chondrodysplasia.

Authors:  P Vandenberg; J S Khillan; D J Prockop; H Helminen; S Kontusaari; L Ala-Kokko
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Tgfbr2 is required for development of the skull vault.

Authors:  Hwa-Seon Seo; Rosa Serra
Journal:  Dev Biol       Date:  2009-08-21       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.